Our Canadian team has written a response to Health Canada's call for engagement on a national strategy for high-cost drugs for rare diseases. Read more about it here: https://www.socialpharmaceuticalinnovation.org/post/canadian-response-to-the-online-engagement-national-strategy-for-high-cost-drugs-for-rare-diseases
What do you think needs to be added or considered when developing a national rare disease strategy?